Compare the efficacy of combination therapy of Deferasirox and Deferiprone in reducing iron load in patients with transfusion-Dependent ß-Thalassemia.

Compare the efficacy of combination Deferasirox and Deferiprone with Deferoxamine and Deferiprone in reducing heart and liver iron load in patients with transfusion-Dependent ß-Thalassemia.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190106042262N1

Enrollment

108

Registered

2019-03-02

Start date

2018-02-19

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

transfusion-Dependent ß-Thalassemia. Beta thalassemia

Interventions

Intervention 1: Intervention group: for six month treated with Defrasirox (in this study we use Osveral 125mg, 250 and 500mg construction of Osvah Company of Iran) with 20-40 mg/kg daily and Deferipro

Eligibility

Sex/Gender

All

Age

10 Years to No maximum

Inclusion criteria

Inclusion criteria: All Patients with transfusion-Dependent ß-Thalassemia with ferritin more than 1000 All Patients with transfusion-Dependent ß-Thalassemia who were not treated with combination iron chelators All Patients with transfusion-Dependent ß-Thalassemia with heart and liver iron load All Patients with transfusion-Dependent ß-Thalassemia with normal liver and renal function All Patients with transfusion-Dependent ß-Thalassemia with age more than 10 years

Exclusion criteria

Exclusion criteria: Gastrointestinal problem before research

Design outcomes

Primary

Measure	Time frame
Heart and liver iron concentration. Timepoint: At the start of research and six month later. Method of measurement: Magnetic resonance imaging T2*.	—

Secondary

Measure	Time frame
Ferritin. Timepoint: At the start of research and third and sixth of study. Method of measurement: Serum ferritin level.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Fazeli Varzaneh

Esfahan University of Medical Sciences

rezaali.fazeli6768@gmail.com+98 31 3527 6082

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026